Content area

|
|

Opsætning af screeningsprogram i Danmark for føtal og neonatal alloimmun trombocytopeni

Forfatter(e)

Caroline Madsen1, Kira Philipsen Prahm2, Cecilia Nilsson3, Lars Henning Pedersen4, Morten Hanefeld Dziegiel5 & Morten Hedegaard6

1) Gastroenheden, Kirurgisk Sektion, Herlev Hospital 2) Gynækologisk Klinik, Rigshospitalet 3) Gynækologisk-obstetrisk Afdeling, Herlev Hospital 4) Institut for Klinisk Medicin, Aarhus Universitet 5) Blodbanken, Rigshospitalet 6) Obstetrisk Klinik, Rigshospitalet Ugeskr Læger 2018;180:V03170211

Reference: 
Ugeskr Læger 2018;180:V03170211
Blad nummer: 
Sidetal: 
2-6
Establishing a screening programme in Denmark for foetal and neonatal alloimmune thrombocytopenia

Foetal and neonatal alloimmune thrombocytopenia (FNAIT) can cause cerebral haemorrhage in newborns. FNAIT occurs in women, who do not have the thrombocyte type human platelet antigen (HPA)-1a and are carrying an HPA-1a positive foetus. Maternal antibodies can cause thrombocytopenia in the foetus or newborn. Antenatal screening for FNAIT can easily be integrated in the already existing national screening programme for rhesus immunisation. Prophylactic treatment with immunoglobulines for pregnancies at risk can prevent neonatal complications. We argue, that the WHO criteria for a screening programme for FNAIT are met.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Patricia Duch | 18/11
1 Kommentar
af Pål Ledaal | 18/11
3 kommentarer
af Hanne Pedersen | 17/11
1 Kommentar
af Mads Aage Toft Kristensen | 16/11
1 Kommentar
af Ketil Bjerregård | 15/11
1 Kommentar
af Jens Lund Ahrenkiel | 15/11
1 Kommentar
af Nicolaj Markus Stilling | 15/11
2 kommentarer